1,https://www.reuters.com/article/brief-cryolife-announces-pricing-of-100/brief-cryolife-announces-pricing-of-100-million-convertible-senior-notes-offering-idUSASA00UDG,2020-06-19T11:30:50Z,BRIEF-CryoLife Announces Pricing Of $100 Million Convertible Senior Notes Offering,June 19 (Reuters) - CryoLife Inc:,* CRYOLIFE ANNOUNCES PRICING OF $100 MILLION CONVERTIBLE SENIOR NOTES OFFERING,* CRYOLIFE - PRICING OF $100 MILLION OF 4.250% CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:
2,https://www.reuters.com/article/brief-cryolife-announces-offering-of-con/brief-cryolife-announces-offering-of-convertible-senior-notes-due-2025-idUSASA00U8C,2020-06-18T11:08:07Z,BRIEF-CryoLife Announces Offering Of Convertible Senior Notes Due 2025,June 18 (Reuters) - CryoLife Inc:,* CRYOLIFE ANNOUNCES OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2025,* CRYOLIFE INC - INTENDS TO OFFER $100 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025,"* CRYOLIFE INC - NOTES ARE EXPECTED TO PAY INTEREST SEMIANNUALLY AND WILL MATURE ON JULY 1, 2025",* CRYOLIFE INC - EXPECTS TO USE NET PROCEEDS FROM OFFERING INCLUDING REPAYMENT OF APPROXIMATELY $30 MILLION OUTSTANDING UNDER ITS REVOLVING CREDIT FACILITY Source text for Eikon: Further company coverage:
3,https://www.reuters.com/article/brief-cryolife-initiates-enrollment-in-p/brief-cryolife-initiates-enrollment-in-proact-xa-clinical-trial-idUSASA00OTE,2020-05-07T22:17:04Z,BRIEF-Cryolife Initiates Enrollment In Proact Xa Clinical Trial,May 7 (Reuters) - CryoLife Inc:,* CRYOLIFE INITIATES ENROLLMENT IN PROACT XA CLINICAL TRIAL Source text for Eikon: Further company coverage:
4,https://www.reuters.com/article/brief-cryolife-expects-q1-2020-revenue-t/brief-cryolife-expects-q1-2020-revenue-to-be-about-65-5-mln-idUSASA00JPD,2020-04-01T20:58:28Z,BRIEF-Cryolife Expects Q1 2020 Revenue To Be About $65.5 Mln,April 1 (Reuters) - CryoLife Inc:,"* AS OF MARCH 31, 2020 CRYOLIFE HAS OVER $60 MILLION IN CASH AND CASH EQUIVALENTS",* EXPECTS Q1 2020 REVENUES TO BE APPROXIMATELY $65.5 MILLION COMPARED TO Q1 2020 REVENUE GUIDANCE OF $67 MILLION TO $69 MILLION,"* IS WITHDRAWING ITS PREVIOUSLY ANNOUNCED Q1 AND FULL YEAR 2020 FINANCIAL GUIDANCE WHICH WAS ISSUED ON FEBRUARY 13, 2020","* CRYOLIFE - DELAYING CERTAIN RESEARCH AND DEVELOPMENT,CLINICAL RESEARCH PROJECTS THAT ARE NOT EXPECTED TO GENERATE REVENUE BEFORE 2023 BUT CONTINUING TO PURSUE THOSE THAT WILL",* WHILE FULL SHORT TERM IMPACT ON US OF PANDEMIC IS NOT KNOWN,* IS OPERATING ALL THREE OF ITS MANUFACTURING SITES AT NEAR FULL PRODUCTION,"* CRYOLIFE - ON MARCH 26,BORROWED ENTIRE AVAILABLE AMOUNT UNDER ITS $30 MILLION REVOLVING CREDIT FACILITY AS A PRECAUTIONARY MEASURE TO INCREASE CASH",* HAS TAKEN PRE-EMPTIVE STEPS TO CURTAIL SPENDING Source text for Eikon: Further company coverage:
5,https://www.reuters.com/article/brief-cryolife-receives-ce-mark-for-e-vi/brief-cryolife-receives-ce-mark-for-e-vita-open-neo-hybrid-stent-graft-idUSFWN2AX0L4,2020-03-04T22:16:16Z,BRIEF-Cryolife Receives CE Mark For E-Vita Open Neo Hybrid Stent Graft,March 4 (Reuters) - CryoLife Inc:,* CRYOLIFE RECEIVES CE MARK FOR E-VITA OPEN NEO™ HYBRID STENT GRAFT Source text for Eikon: Further company coverage:
6,https://www.reuters.com/article/brief-cryolife-receives-ce-mark-for-on-x/brief-cryolife-receives-ce-mark-for-on-x-ascending-aortic-prosthesis-idUSFWN2AR18C,2020-02-27T21:26:32Z,BRIEF-Cryolife Receives CE Mark For On-X Ascending Aortic Prosthesis,Feb 27 (Reuters) - CryoLife Inc:,* CRYOLIFE RECEIVES CE MARK FOR ON-X® ASCENDING AORTIC PROSTHESIS Source text for Eikon: Further company coverage:
7,https://www.reuters.com/article/brief-cryolife-q4-revenue-697-mln-vs-ref/brief-cryolife-q4-revenue-69-7-mln-vs-refinitiv-ibes-estimate-of-70-8-mln-idUSASA00DFJ,2020-02-13T21:56:35Z,BRIEF-Cryolife Q4 Revenue $69.7 Mln Vs Refinitiv Ibes Estimate Of $70.8 Mln,Feb 13 (Reuters) - CryoLife Inc:,* CRYOLIFE REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS,* Q4 REVENUE $69.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.8 MILLION,* Q4 EARNINGS PER SHARE ESTIMATE $0.08 -- REFINITIV IBES DATA,"* “2020 REVENUE GUIDANCE ASSUMES NO CONTRIBUTION DURING 2020 FROM BIOGLUE IN CHINA, PERCLOT IN U.S., OR TMR HANDPIECES”",* Q4 REVENUE VIEW $70.8 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
